Complementary strategies to be used in conjunction with animal models for multiple sclerosis drug discovery: adapting preclinical validation of drug candidates to the need of remyelinating strategies.

Date publication

juillet 2024

Journal

Expert opinion on drug discovery

Auteurs

Membres identifiés du Cancéropôle Est :
Dr BAGNARD Dominique

Tous les auteurs :
Charmarke-Askar I, Spenlé C, Bagnard D

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/39039755

Résumé

The quest for novel MS therapies focuses on promoting remyelination and neuroprotection, necessitating innovative drug design paradigms and robust preclinical validation methods to ensure efficient clinical translation. The complexity of new drugs action mechanisms is strengthening the need for solid biological validation attempting to address all possible pitfalls and biases precluding access to efficient and safe drugs.

Mots clés

Multiple sclerosis, drug design, drug screening, in vitro models, in vivo models, preclinical validation

Référence

Expert Opin Drug Discov. 2024 07 22;:1-10